RevenueNet IncomeP/EP/SEBITDividendStocksMarket capitalizationDebtLiabilitiesEquityAAQSEmployeesROEROAROCE
Tianjin Pharmaceutical Da Ren Tang Group Corp Stock

Tianjin Pharmaceutical Da Ren Tang Group Corp ROE 2024

Tianjin Pharmaceutical Da Ren Tang Group Corp ROE

0.15

Ticker

600329.SS

ISIN

CNE000001808

In 2024, Tianjin Pharmaceutical Da Ren Tang Group Corp's return on equity (ROE) was 0.15, a 13.12% increase from the 0.13 ROE in the previous year.

Tianjin Pharmaceutical Da Ren Tang Group Corp Aktienanalyse

What does Tianjin Pharmaceutical Da Ren Tang Group Corp do?

Tianjin Zhongxin Pharmaceutical Group Corp Ltd is one of the leading pharmaceutical companies in China. It was founded in 1994 and is headquartered in the city of Tianjin in the northern part of the country. Zhongxin is a publicly traded company and employs over 6,000 employees. The business model of Zhongxin is diversified and includes manufacturing, research and development, sales, and marketing of pharmaceuticals and medical devices. The company strives to provide its customers with high-quality products and services and operates in various specialized areas. One of Zhongxin's main divisions is the manufacturing of pharmaceutical products. The company specializes in the production of cardiology, gastroenterology, oncology, and traditional Chinese medicines. Zhongxin operates multiple production facilities in China and has a productive R&D department focused on drug development. Another important part of Zhongxin's business is the distribution of its products. The company operates several distribution centers in China and is also increasing its presence in international markets. Distribution is done either directly to end customers or through intermediaries. In addition to the sale of medications, Zhongxin is also involved in medical wholesale activities, including retail and delivery of medical equipment and instruments. The company is capable of providing all types of medical devices and instruments from imaging and diagnostics to surgical instruments and implants. Zhongxin also has a specialized chemicals and raw materials division focused on the production of pharmaceutical active ingredients and intermediates. This gives the company additional control over the quality of its products as it is able to produce raw materials itself. The company is always seeking new innovations and heavily investing in research and development. In recent times, Zhongxin has invested in the development of biotech and nucleic acid therapies and intends to develop further innovative treatment methods. Zhongxin has also developed a strong presence in international markets in recent years. It has subsidiaries in several countries including the USA, Australia, Japan, and Europe. The company engages in joint ventures and strategic partnerships to enhance its raw material procurement and expand its reach internationally. Overall, Tianjin Zhongxin Pharmaceutical Group Corp Ltd is a significant player in the pharmaceutical industry in China and on the international stage. The company has established a reputation as a reliable producer of high-quality medical products and services and continues to strive for success through innovation and expansion. Tianjin Pharmaceutical Da Ren Tang Group Corp ist eines der beliebtesten Unternehmen auf Eulerpool.com.

ROE Details

Decoding Tianjin Pharmaceutical Da Ren Tang Group Corp's Return on Equity (ROE)

Tianjin Pharmaceutical Da Ren Tang Group Corp's Return on Equity (ROE) is a fundamental metric evaluating the company's profitability relative to its equity. Calculated by dividing net income by shareholder's equity, ROE illustrates how effectively the company is generating profits from shareholders’ investments. A higher ROE represents enhanced efficiency and profitability.

Year-to-Year Comparison

Analyzing Tianjin Pharmaceutical Da Ren Tang Group Corp's ROE on a yearly basis aids in tracking its profitability trends and financial performance. An increasing ROE suggests enhanced profitability and value generation for shareholders, whereas a declining ROE may indicate issues in profit generation or equity management.

Impact on Investments

Tianjin Pharmaceutical Da Ren Tang Group Corp's ROE is instrumental for investors assessing the company's profitability, efficiency, and investment attractiveness. A robust ROE indicates the firm’s adeptness at converting equity investments into profits, thereby enhancing its appeal to potential and current investors.

Interpreting ROE Fluctuations

Changes in Tianjin Pharmaceutical Da Ren Tang Group Corp’s ROE can emanate from variations in net income, equity capital, or both. These fluctuations are scrutinized to evaluate management’s effectiveness, financial strategies, and the inherent risks and opportunities, aiding investors in making informed decisions.

Frequently Asked Questions about Tianjin Pharmaceutical Da Ren Tang Group Corp stock

What is the ROE (Return on Equity) of Tianjin Pharmaceutical Da Ren Tang Group Corp this year?

The ROE of Tianjin Pharmaceutical Da Ren Tang Group Corp this year is 0.15 undefined.

How has the Return on Equity (ROE) of Tianjin Pharmaceutical Da Ren Tang Group Corp developed compared to the previous year?

The ROE of Tianjin Pharmaceutical Da Ren Tang Group Corp has increased by 13.12% increased compared to the previous year.

What impact does a high ROE (Return on Equity) have on investors of Tianjin Pharmaceutical Da Ren Tang Group Corp?

A high ROE indicates that Tianjin Pharmaceutical Da Ren Tang Group Corp generates good returns on capital and is successful in monetizing its investments. This is a positive indicator for investors.

What impact does a low ROE (Return on Equity) have on investors of Tianjin Pharmaceutical Da Ren Tang Group Corp?

A low ROE can indicate that Tianjin Pharmaceutical Da Ren Tang Group Corp is having difficulties monetizing its investments successfully and can be a negative signal for investors.

How does a change in the ROE (Return on Equity) of Tianjin Pharmaceutical Da Ren Tang Group Corp affect the company?

A change in ROE (Return on Equity) of Tianjin Pharmaceutical Da Ren Tang Group Corp can be an indicator of the financial performance of the company and demonstrate how successful the company is compared to other companies in the same industry.

How to calculate the ROE (Return on Equity) of Tianjin Pharmaceutical Da Ren Tang Group Corp?

The ROE (Return on Equity) is calculated by dividing the company's profit by the total equity. The formula is: ROE = Profit / Total equity.

Which factors influence the ROE (Return on Equity) of Tianjin Pharmaceutical Da Ren Tang Group Corp?

Some factors that can influence Tianjin Pharmaceutical Da Ren Tang Group Corp's Return on Equity (ROE) include the efficiency in using equity, the profitability of the company, and the financing structure.

What strategic measures can take to improve the ROE (Return on Equity)?

To improve the Return on Equity (ROE), can take measures such as cost savings, increasing revenue, improving efficiency in the use of equity, and making changes in the financing structure. It is important for the company to conduct a thorough review of its financial situation to determine the best strategic actions to improve ROE.

How much dividend does Tianjin Pharmaceutical Da Ren Tang Group Corp pay?

Over the past 12 months, Tianjin Pharmaceutical Da Ren Tang Group Corp paid a dividend of 1.12 CNY . This corresponds to a dividend yield of about 3.47 %. For the coming 12 months, Tianjin Pharmaceutical Da Ren Tang Group Corp is expected to pay a dividend of 1.21 CNY.

What is the dividend yield of Tianjin Pharmaceutical Da Ren Tang Group Corp?

The current dividend yield of Tianjin Pharmaceutical Da Ren Tang Group Corp is 3.47 %.

When does Tianjin Pharmaceutical Da Ren Tang Group Corp pay dividends?

Tianjin Pharmaceutical Da Ren Tang Group Corp pays a quarterly dividend. This is distributed in the months of July, July, July, August.

How secure is the dividend of Tianjin Pharmaceutical Da Ren Tang Group Corp?

Tianjin Pharmaceutical Da Ren Tang Group Corp paid dividends every year for the past 16 years.

What is the dividend of Tianjin Pharmaceutical Da Ren Tang Group Corp?

For the upcoming 12 months, dividends amounting to 1.21 CNY are expected. This corresponds to a dividend yield of 3.75 %.

In which sector is Tianjin Pharmaceutical Da Ren Tang Group Corp located?

Tianjin Pharmaceutical Da Ren Tang Group Corp is assigned to the 'Health' sector.

Wann musste ich die Aktien von Tianjin Pharmaceutical Da Ren Tang Group Corp kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Tianjin Pharmaceutical Da Ren Tang Group Corp from 7/12/2024 amounting to 1.28 CNY, you needed to have the stock in your portfolio before the ex-date on 7/12/2024.

When did Tianjin Pharmaceutical Da Ren Tang Group Corp pay the last dividend?

The last dividend was paid out on 7/12/2024.

What was the dividend of Tianjin Pharmaceutical Da Ren Tang Group Corp in the year 2023?

In the year 2023, Tianjin Pharmaceutical Da Ren Tang Group Corp distributed 0.5 CNY as dividends.

In which currency does Tianjin Pharmaceutical Da Ren Tang Group Corp pay out the dividend?

The dividends of Tianjin Pharmaceutical Da Ren Tang Group Corp are distributed in CNY.

Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.

Andere Kennzahlen von Tianjin Pharmaceutical Da Ren Tang Group Corp

Our stock analysis for Tianjin Pharmaceutical Da Ren Tang Group Corp Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Tianjin Pharmaceutical Da Ren Tang Group Corp Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.